Objectives: Transforming anaplastic lymphoma kinase (ALK) gene rearrangements are well known as a unique subset of non-small cell lung cancer (NSCLC) with mutations other than EGFR. Currently, crizotinib is the standard first-line treatment for ALK-positive NSCLC. Conclusion: Considering this rare SOS1-ALK fusion and remarkable response to an ALK-inhibitor, it is important to be aware of the presence of SOS1-ALK fusions in patients with advanced NSCLC to better guide targeted therapy. Precision methods, such as NGS for oncogenic alteration detection, should also be encouraged in clinical practice. READ ARTICLE
Lung Cancer DOI:10.1016/j.lungcan.2020.02.012
Authors: Hua-fei Chen, Wen-xian Wang, Chun-wei Xu, Li-chao Huang, Xiao-feng Li, Gang Lan, Zhan-qiang Zhai, You-cai Zhu, Kai-qi Du, Lei Lei, Mei-yu Fang
